Children playing T-ball

DOSING INFO AND SCHEDULE FIT

PRIORIX: an MMR schedule you know1,2

The dosing schedule for PRIORIX aligns with the CDC-recommended routine immunization schedule for MMR.1,2 PRIORIX has the same indication as M-M-R II.1,3

PRIORIX dosing and schedule

For subcutaneous injection only. After reconstitution, a single dose of PRIORIX is approximately 0.5 mL.1

CDC recommends that MMR and varicella vaccines be administered separately for the first dose, unless parents or guardians express a preference for MMRV.2

CDC=Centers for Disease Control and Prevention; MMR=measles, mumps, and rubella; MMRV=measles, mumps, rubella, and varicella.

PRIORIX Dose 11 PRIORIX Dose 21

Administered at 12 through 15 months of age

Administered at 4 through 6 years of age

If PRIORIX is not administered according to this schedule and 2 doses of MMR virus vaccine are recommended for an individual, there should be a minimum of 4 weeks between the first and second dose1

CDC recommends that MMR and varicella vaccines be administered separately for the first dose, unless parents or guardians express a preference for MMRV.2

CDC=Centers for Disease Control and Prevention; MMR=measles, mumps, and rubella; MMRV=measles, mumps, rubella, and varicella.

INDICATION & IMPORTANT SAFETY INFO

INDICATION FOR PRIORIX

IMPORTANT SAFETY INFORMATION FOR PRIORIX

INDICATION FOR PRIORIX

PRIORIX is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age and older.

IMPORTANT SAFETY INFORMATION FOR PRIORIX

  • Contraindications for PRIORIX: Do not administer PRIORIX to individuals with a history of severe allergic reactions (eg, anaphylaxis) to any component of the vaccine or after a previous dose of any measles, mumps, and rubella virus-containing vaccine. Do not administer PRIORIX to individuals who are immunodeficient or immunosuppressed due to disease or medical therapy. These individuals are at risk of disseminated vaccine virus infection. Do not administer PRIORIX to individuals who are pregnant. Pregnancy should be avoided for 1 month after vaccination
  • Appropriate medical treatment used to manage immediate allergic reactions must be available in the event an acute anaphylactic reaction occurs following administration of PRIORIX
  • There is a risk of febrile seizures following immunization with PRIORIX
  • Thrombocytopenia and thrombocytopenic purpura have been reported following vaccination with PRIORIX
  • Syncope (fainting) can occur in association with administration of injectable vaccines, including PRIORIX. Procedures should be in place to avoid injury from fainting
  • The tip caps of the prefilled syringes of diluent contain natural rubber latex, which may cause allergic reactions
  • Vaccination with PRIORIX may not result in protection in all vaccine recipients
  • In clinical trials, the most commonly reported (≥10%) solicited adverse reactions were:
    • Age 12 through 15 months–local: pain (26%) and redness (25%); systemic: irritability (63%), loss of appetite (45%), drowsiness (45%), and fever (35%)
    • Age 4 through 6 years–local: pain (41%), redness (22%) and swelling (11%); systemic: loss of appetite (21%), drowsiness (27%), and fever (24%)
    • Age 7 years and older–local: pain (12%) and redness (12%)
  • Administration of immune globulins and other blood products concurrently with PRIORIX may interfere with the expected immune response to the vaccine
  • If a tuberculin test is to be done, it should be administered either any time before, simultaneously with, or at least 4 weeks after PRIORIX to avoid false-negative results

Please see full Prescribing Information for PRIORIX.

References

  1. Prescribing Information for PRIORIX.

  2. Centers for Disease Control and Prevention. Recommended child and adolescent immunization schedule for ages 18 years or younger, United States, 2022. Reviewed February 17, 2022. Accessed September 1, 2022. https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf

  3. Prescribing Information for M-M-R II.